Share

News about the EORTC Liaison Offices in the United Kingdom and in France

This month a new UK-based EORTC Liaison Officer, Liz Flackett (e.flackett[at]ncrn.org.uk), joined the EORTC Liaison Office in the UK. This Office is jointly supported by the EORTC, the National Cancer Research Network (NCRN) and Cancer Research UK (CRUK) has taken her position. In June, a Liaison Office in France will be set up in partnership between the EORTC and the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).

These Liaison Offices are aimed at fostering collaborative clinical cancer research between the EORTC and other international cancer research organisations and also supporting EORTC members in order to facilitate administrative and regulatory aspects of conducting EORTC trials.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023